

# Advisory Committee on

## Blood Safety and Availability Department of Health and Human Services

Thirty-sixth Meeting April 30 & May 1, 2009

#### The Universities at Shady Grove

9630 Gudelsky Drive Rockville, MD 20850 Phone: (301) 738-6000

#### Thursday, April 30, 2009

08:00	Doors Open	Open to the Public		
08:30	Call to Order	Arthur W. Bracey, MD Chairman		
08:35	Roll Call Conflict of Interest Introduction of New Committee Members	Jerry A. Holmberg, PhD Executive Secretary		
08:40	Swearing in of New Committee Members	Ms Renee Wilson		
09:00	Charge to the Committee	Arthur W. Bracey, MD		
Committee Updates				
09:30	An Update on Patient Safety Organizations and Potential Role in Transfusion and Transplantation Safety	Amy Helwig, MD, MS Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality		
9:50	Break			

### US BIOVIGILANCE: EFFORTS TO BRIDGE A CRITICAL DONOR AND PATIENT SAFETY GAP

A work product of the Public Health Service (PHS) Biovigilance Task Group in response to recommendations of the ACBSA

10:05	Public Health Service (PHS) Biovi Group	gilance Task	Matthew Kuehnert, MD Jerry Holmberg, PhD Alan Williams, PhD
11:00	Committee Discussion		Committee
11:30	Lunch  Decision Making Paradigm in  Transfusion Safety		
12:30	Issues Surrounding Transfusion S Strategies, Interventions, and Dec	•	Jeffrey McCullough, MD American Red Cross Chair, Transfusion Medicine Director, Institute for Engineering in Medicine University of Minnesota
1:00	Ethical Considerations in Transfus Transplantation Safety: <i>variables</i> into the transfusion and transplan equation and society's expectation	that factor tation safety	Evan DeRenzo, PhD Senor Clinical Bioethicist Center for Ethics at Washington Hospital Center
1:30	Committee Discussion		Arthur W. Bracey, MD
2:00	Intervention Decisions in Emergin Diseases	g Infectious	Simone Glynn MD, MSc, MPH Branch Chief Transfusion Medicine and Cellular Therapeutics Branch Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute
2:30	Committee Discussion		Arthur W. Bracey, MD
3:00	Break		
3:15	Comparative Effectiveness : Decision-based Evidence Making		Sean Tunis, MD, MSc Center for Medical Technology Policy
4:00	Comparative Effectiveness Reseaview from NHLBI	arch: The	Michael S. Lauer, MD, FACC, FAHA Director, Division of Prevention and Population Science, NHLBI, NIH
Agenda is subject to change		Page 2	4/28/2009

4:30	Open Public Comment	Committee of Ten Thousand Hemophilia Society of America			
5:00	Adjourn for the Day	Arthur W. Bracey, M.D.			
	Friday, May 1, 2009				
08:00	Doors Open	Open to the Public			
08:30	Call to Order and Roll Call	Arthur W. Bracey, M.D. Jerry A. Holmberg, Ph.D.			
08:35	Comments to the Committee	Rear Admiral Steven Galson, MD, MPH Acting Assistant Secretary Acting Surgeon General Office of Public Health and Science			
09:15	Cost Benefit Analysis and the Factor of Risk in Advancing New Technologies	James Aubuchon. MD President and CEO Puget Sound Blood Center Seattle, WA			
09:45	Modeling Health Economics of Transfusion and Transplantation Safety	Brian Custer, MPH PhD Associate Investigator Blood Systems Research Institute			
10:15	Break				
10:30	Open Public Comments	National Hemophilia Foundation AABB ARC ABC AATB UNOS			
11:00	Committee Discussion	Arthur W. Bracey, MD			
12:00	Lunch				
1:00	Committee Discussion				
3:00 4:00	Break Meeting Adjournment	Arthur W. Bracey, M.D.			